Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer

Ben C. Creelan,1,* Scott Antonia,2 Gerold Bepler,3 Timothy J. Garrett,4 George R. Simon5 and Hemat H. Soliman2

1University of South Florida; Tampa, FL USA; 2H. Lee Moffitt Cancer Center; Tampa, FL USA; 3Karmanos Cancer Institute; Wayne State University; Detroit, MI USA; 4University of Florida; Gainesville, FL USA; 5MD Anderson Cancer Center; Houston, TX USA

Keywords: indoleamine 2,3 dioxygenase, innate immunity, kynurenine, non-small cell lung cancer, tryptophan

Abbreviations: AJCC, American joint committee on cancer; AUC, area under the curve; BIN1, bridging integrator 1; CI, confidence interval; CT, computed tomography; CTLA-4, cytotoxic T-lymphocyte antigen 4; D-1MT, 1-methyl-D-tryptophan; ECOG, Eastern Cooperative Oncology Group; GCN-2, general control nonrepressed 2; HPLC, high performance liquid chromatography; HR, hazard ratio; IDO, indoleamine 2,3 dioxygenase; IFN, interferon; IHC, immunohistochemistry; ILT, immunoglobulin-like transcript; IPMN, intraductal papillary mucinous neoplasm; Kyn, kynurenine; MS, mass spectrometry; mTOR, mammalian target of rapamycin; NCT, national clinical trial; NSCLC, non-small cell lung cancer; OS, overall survival; PET, positron emission tomography; PFS, progression-free survival; PKCθ, protein kinase C θ; RECIST, response evaluation criteria in solid tumors; STAT1, signal transducer and activator of transcription 1; TGF, transforming growth factor; TIL, tumor-infiltrating lymphocyte; Trp, tryptophan

Indoleamine 2,3-dioxygenase (IDO) has recently been proposed to account for tumor-induced immunosuppression by influencing the conversion of tryptophan (Trp) into kynurenine (Kyn). The objective of our study was to correlate IDO activity with disease outcome in non-small cell lung cancer (NSCLC) patients treated with multimodal combination therapy. In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. The mean plasma Kyn/Trp ratio was used as a surrogate indicator of IDO activity. The 33 participants were distributed as follows: 15 females, 18 males; median age = 62; median overall survival (OS) = 22.4 (95% CI 19.3–25.1) months; median progression-free survival (PFS) = 11.5 (95% CI 6.7–16.3) months. The mean Kyn/Trp ratio at baseline (4.5 ± 2.8) was higher than that of healthy controls (2.9 ± 1.9, p = 0.03) and increased after induction therapy (5.2 ± 3.2, p = 0.08) and chemoradiation (5.8 ± 3.9, p = 0.01). The post-treatment Kyn/Trp ratio and radiologic responses were not significantly associated at any time point. No significant correlation was found between baseline Kyn/Trp ratios and OS (HR = 1.1, 95% CI 0.45–2.5) or PFS (HR = 0.74, 95% CI 0.30–1.82). A post-induction chemotherapy increase in IDO activity portended worse OS (HR = 0.43, 95% CI 0.19–0.95, p = 0.037) and PFS (HR = 0.47, 95% CI 0.22–1.0, p = 0.055). This observed increase in IDO transcription may be a means for tumors to evade immunosurveillance.

Introduction

Indoleamine 2,3-dioxygenase (IDO) is a cytosolic protein that catalyzes the rate-limiting step of human tryptophan (Trp) metabolism. Trp depletion induces effector T cells to undergo a G1 cell cycle arrest1 and triggers an integrated stress response pathway that involves general control nonrepressed 2 (GCN2) signaling and eukaryotic initiation factor 2α (eIF2α) phosphorylation.2,3 IDO also causes systemic anergy by inducing naive T cells to differentiate into CD4+CD25+FOXP3+ regulatory T cells.4 Dendritic cells respond to low Trp levels by upregulating inhibitory factors such as immunoglobulin-like transcript 3 (ILT3), ILT4 and transforming growth factor β1 (TGF-β1), thus becoming immunosuppressive.5 Moreover, Trp metabolites such as kynurenine (Kyn), quinolinic acid, and picolinic acid exert cytotoxic effects on CD8+ tumor-infiltrating lymphocytes (TILs) and CD4+ Tγδ1 cells.6,7 The IDO-mediated deprivation of Trp also inhibits the immunomodulatory kinases mammalian target of rapamycin.
of rapamycin (mTOR) and protein kinase C Θ (PKCΘ), thereby inhibiting autophagy. In fact, IDO is overexpressed by many human cancers and may serve as an escape mechanism from host immunity. For example, in humans and animals, the induction of IDO limits the immune response to dendritic cell-based anticancer vaccines. Cancer cells bearing mutations in the oncosuppressor gene BIN1 are stimulated by interferon γ (IFNγ) to overexpress IDO, leading to increased intracellular levels of signal transducer and activator of transcription 1 (STAT1) and nuclear factor κB (NFκB). Thus, IDO may be an important stimulator of immune tolerance in human cancer.

Non-small cell lung cancer (NSCLC) is an aggressive epithelial malignancy that often overexpresses the mRNA coding for IDO. NSCLC has an annual incidence of 1.61 million people worldwide, and 83 percent of NSCLC patients will eventually die of their cancer. Locoregionally-advanced NSCLC comprises more than one-third of cases at presentation and is classified as Stage III. Over three quarters of Stage III NSCLC patients are technically or medically inoperable. Chemotherapy and concurrent radiation is the standard therapy for inoperable Stage III NSCLC, but the five year overall survival (OS) remains poor, that is, 20% and 8% for IIIA and IIIB disease, respectively. Such an aggressive malignant phenotype has been hypothesized to stem from an innate resistance of NSCLC to chemotherapy and to its ability to evade immnosurveillance. However, the role of IDO in mediating immune tolerance in NSCLC is unclear.

Trp catabolism in lung cancer patients is associated with advanced disease stage. This said, how IDO activity changes

---

**Figure 1.** Trial flow diagram. Induction chemotherapy: gemcitabine and carboplatin. Thoracic radiation: 74 Gy conformal. Concurrent chemotherapy: paclitaxel and carboplatin.

**Table 1.** Demographics and baseline measurements

| Characteristics                  | Patients n (%) | Kyn (μM) Mean ± SD | Trp (μM) Mean ± SD | Kyn/Trp (μM/μM) Mean ± SD |
|----------------------------------|----------------|--------------------|--------------------|---------------------------|
| Total                            | 33             | 1.6 ± 0.8          | 37.9 ± 8.5         | 4.5 ± 2.8                 |
| Age in years (Median ± SD)       |                | 62.4 ± 7.9         |                    |                           |
| Age < 65 y                        | 19 (58)        | 1.6 ± 0.9          | 40.3 ± 8.2         | 4.0 ± 2.3                 |
| Age 65 y                          | 14 (42)        | 1.6 ± 0.7          | 34.7 ± 8.1         | 5.1 ± 3.3                 |
| Race                              |                |                    |                    |                           |
| Caucasian                         | 31 (94)        | 1.6 ± 0.8          | 37.9 ± 8.8         | 4.6 ± 2.8                 |
| Asian                             | 1 (3)          | 0.9                | 36.5               | 2.5                       |
| Black                             | 1 (3)          | 1.1                | 37.9               | 2.9                       |
| Gender                            |                |                    |                    |                           |
| Female                            | 15 (45)        | 1.6 ± 0.8          | 36.3 ± 8.0         | 4.9 ± 2.3                 |
| Male                              | 18 (55)        | 1.5 ± 0.8          | 38.9 ± 8.9         | 4.2 ± 1.9                 |
| ECOG* performance status          |                |                    |                    |                           |
| PS 0                              | 11 (33)        | 1.5 ± 1.0          | 37.4 ± 10.7        | 5.5 ± 2.3                 |
| PS 1                              | 22 (66)        | 1.6 ± 0.7          | 38.0 ± 8.0         | 4.6 ± 1.6                 |
| Smoking status                    |                |                    |                    |                           |
| Active smoker                     | 12 (36)        | 1.7 ± 0.8          | 38.6 ± 7.7         | 4.5 ± 3.1                 |
| Former smoker                     | 21 (64)        | 1.5 ± 0.8          | 37.4 ± 9.3         | 4.4 ± 2.3                 |
| AJCC * clinical stage             |                |                    |                    |                           |
| IIIA                              | 16 (48)        | 1.6 ± 0.9          | 38.2 ± 9.2         | 4.7 ± 2.7                 |
| IIIB                              | 17 (52)        | 1.6 ± 0.7          | 37.5 ± 8.0         | 4.3 ± 2.2                 |
| Histotyope of NSCLC               |                |                    |                    |                           |
| Adenocarcinoma                    | 11 (33)        | 1.5 ± 0.7          | 37.4 ± 7.2         | 4.0 ± 1.3                 |
| Squamous cell                     | 10 (30)        | 1.4 ± 0.8          | 39.7 ± 7.4         | 3.8 ± 3.3                 |
| Other ‡                          | 12 (36)        | 1.8 ± 0.8          | 36.9 ± 10.7        | 5.3 ± 2.3                 |

*Eastern Cooperative Oncology Group. *American Joint Committee on Cancer. ‡Includes bronchoalveolar, large cell and “not otherwise specified.” No statistically significant mean difference was detected for any comparison of the groups presented (p < 0.05, Wilcoxon rank-sum test).
after chemotherapy or radiation in NSCLC patients is unclear. The abrogation of BIN1 causes IDO overexpression and promotes NSCLC in animals.26 NSCLC-infiltrating lymphocytes are often anergic and hypoproliferative,27 and the overexpression of IDO in the NSCLC peritumoral stroma is associated with poor prognosis.28 Based on these observations, we hypothesized that IDO activity may increase in Stage III NSCLC patients undergoing conventional multimodal therapy. Since Kyn is the primary metabolite of Trp metabolism, the plasma Kyn/Trp ratio has been used as a surrogate indicator of IDO activity.29,30 Our objective was to prospectively correlate serial changes in IDO activity, as measured by the plasma Kyn/Trp ratio, with radiologic response and survival in NSCLC patients treated with multimodal therapy.

Results

Forty-three participants were enrolled from December 2003 to February 2006. Of 39 participants initiated on treatment, 33 had plasma drawn at Time 0 evaluable for mass spectrometry (Fig. 1). We observed no trends between baseline plasma metabolites and demographic features such as age, race, gender, and performance status (Table 1). Moreover, we observed no correlations between baseline plasma markers and tumor characteristics such as histology or clinical stage. However, these correlative studies were limited by a relatively low statistical power. To assess the presence of outliers, we used a formal outlier test, the extreme studentized deviate (ESD) method with p < 0.05, which identified one outlier at time 0 (14.5 with z = 3.6) and no outliers at Time 1 and Time 2. To further assess the influence of outliers, we examined the clinicopathologic features of the six participants displaying the highest Kyn/Trp ratio at Time 0 and Time 1 compared with the rest of the cohort. No statistically significant differences in age, survival, tumor burden, chemotherapy response, white blood count and serum albumin was observed.

Compared with a sample of 24 healthy controls (2.9 ± 1.9), participants had higher mean Kyn/Trp ratio at baseline (4.5 ± 2.8, p = 0.03) (Fig. 2). Mean plasma Kyn/Trp ratios increased after induction chemotherapy (Time 0 to Time 1, 5.2 ± 3.2, p = 0.08), and after concurrent definitive chemoradiation (Time 1 to Time 2, 5.8 ± 3.9, p = 0.01). No correlation was observed between baseline plasma Kyn/Trp ratios and primary tumor cross-sectional area (r = 0.10, 95% CI −0.27–0.43) or total cross-sectional area of all target lesions on CT (CT) (r = 0.02, 95% CI −0.33–0.37) (Fig. 3A). Likewise, no appreciable correlation was observed between changes in plasma Kyn/Trp ratios from Time 0 to Time 1 (ΔIDO1) and changes in primary tumor cross-sectional area (r = −0.25, 95% CI −0.56–0.12) or changes in total cross-sectional area of all target lesions on CT (r = −0.17, 95% CI −0.50–0.20) (Fig. 3B). After induction chemotherapy, we observed one complete response, 11 partial responses and 21 patients with stable disease. Using response evaluation criteria in solid tumors (RECIST), a non-statistically significant association was observed between improved radiologic responses and plasma Kyn/Trp ratios at Time 1, with p = 0.34 (Fig. 4A). A similar non-significant trend was observed between radiologic responses and plasma Kyn/Trp ratios at Time 2, with p = 0.19 (Fig. 4B). To index the shift in IDO activity after chemotherapy, the differences in Kyn/Trp ratios between Time 0 and Time 1 (ΔIDO1) and between Time 1 and Time 2 (ΔIDO2) were calculated. Participants were subdivided into two groups based on the median ΔIDO value. Using RECIST to define the percentage of response, a non-significant trend was observed between radiologic responses at Time 1 and ΔIDO (Fig. 5).

Median OS was 22.4 mo (95% CI 19.3–25.1) and median progression-free survival (PFS) 11.5 mo (95% CI 6.7–16.3) (Table 2).
Baseline Kyn/Trp ratios were not significantly associated with OS (HR = 0.88, 95% CI 0.41–1.35). After induction chemotherapy at Time 1, patients with high ΔIDO1 had worse OS (p = 0.037) and a trend toward worse PFS (p = 0.055) as compared with individuals with low ΔIDO1 (Fig. 6). However, no association was found after chemoradiation between ΔIDO1 and OS (HR = 1.1, 95% CI 0.45–2.5) or PFS (HR = 0.74, 95% CI 0.30–1.82).

**Discussion**

To our knowledge, this is the first report to serially explore changes in plasma IDO activity during the treatment of Stage III NSCLC patients, as measured by Kyn/Trp ratios. We found that IDO activity was higher in cancer patients than in healthy individuals, consistent with previous observations in lung cancer, colorectal carcinoma, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, melanoma, colorectal carcinoma, esophageal cancer, thyroid carcinoma, acute myelogenous leukemia, breast cancer and gynecologic cancer patients. This observation lends credence to the hypothesis that cancer cells may stimulate dendritic cells to express IDO or may directly overexpress the enzyme. Indeed, NSCLCs exhibit high Trp metabolism as monitored by α-methyl-tryptophan positron emission tomography (PET) imaging as compared with normal tissues. We could not observe a strong correlation between baseline tumor sizes and Kyn/Trp ratios, or a strong correlation between changes in tumor size and changes in Kyn/Trp ratios. This suggests that Kyn/Trp ratios are unlikely to be determined by the tumor burden alone.

Consistent with previous observations in NSCLC patients, we did not find a correlation between baseline IDO activity and survival. Several authors have examined the relationship between IDO activity and survival in other cancers (Table 3). Of interest, studies based on the immunohistochemical detection of IDO more often reported an unfavorable role for IDO than studies based on the detection of IDO mRNA levels (16:1 vs 1:6,
Melanoma biopsies at baseline and during regression in response to chemotherapy. Along these lines, it has recently been reported that a subset of NSCLC patients with favorable radiologic responses after chemotherapy exhibit a significant decrease in IDO activity within monocytes as compared with baseline conditions. Tumors may generate a hostile microenvironment that impedes host antitumor immune response. Interestingly, no changes in the expression of IDO by tumor cells was observed in melanoma biopsies at baseline and during regression in response to tremelimumab treatment, suggesting that IDO activity may not be influenced by cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibition.

Several aspects of our report necessitate a more detailed investigation before firm conclusions can be drawn. Due to a small sample size, our trial was statistically underpowered to detect any significant association between Kyn/Trp ratios and demographic characteristics. Likewise, our patient sample was too small to establish a stepwise dose-effect relationship between IDO activity and clinical outcome. Next, tissues were not available for the immunohistochemical detection of IDO, so we used plasma Kyn/Trp ratios as a convenient surrogate marker for IDO activity. Other studies have used plasma Kyn/Trp ratios as an indirect measure for IDO activity (Table 3) and these correlate well with immunohistochemical data. However, plasma Kyn/Trp ratios are not a direct measure of IDO activity. In particular, other Trp catabolizing enzymes, including tryptophan 2,3-dioxygenase and the IDO splice variant known as IDO2 contribute to Kyn production as well. Moreover, our study did not mandate uniform timing for blood draws. Since plasma Trp levels may vary by as much as 20% in the same subject depending on the distance of the last meal and the diurnal cycle, we acknowledge this as a potential confounder. Nonetheless, plasma Kyn has only minor diurnal variation, and the changes that we observed in Kyn/Trp ratios appeared predominantly attributable to Kyn (Fig. 2). Another drawback of the present study is that correlative immunologic markers, such as FOXP3 expression, CD3 activity, and IFN production were not measured. Additional markers may help to substantiate the putative role of IDO in this patient population. Moreover, conclusions cannot be drawn about the effect of individual chemotherapy agents, which are known to have specific immunomodulatory properties. Finally, our calculations were performed without multiple comparison rules. Thus, the possibility exists that the observed associations could stem from family-wise errors. In view of all these limitations, our results should be strictly viewed as exploratory.

In summary, our findings may serve as a rationale for larger studies correlating changes in the Kyn/Trp ratio with clinical parameters during standard multimodal therapy against NSCLC. As IDO may contribute to the resistance of NSCLC to therapy, this clinical setting may be a fertile area for the investigation of the antineoplastic effects of IDO inhibitors, such asl-methyl-D-tryptophan (D-1MT).

Materials and Methods

Patients. The design of the clinical trial has been previously described. Briefly, our single-arm trial used induction gemcitabine (1 g/m²) on day 1 and day 8 and carboplatin (AUC = 5) on day 1 given at 4-week intervals for two cycles. This was followed by weekly carboplatin (AUC = 2) and paclitaxel (50 mg/m²) with concurrent conformal radiation (dose = 74 Gy ± 5%) administered over 40 daily fractions. Plasma was collected at baseline (Time 0), after induction at week 9 (Time 1), and after
concurrent therapy at week 25–26 (Time 2). All participants enrolled had previously untreated clinical Stage IIIA or “dry” IIIB NSCLC, as determined by American Joint Committee on Cancer (AJCC) criteria v. 6. None of these patients had received previous chemotherapy or radiation.

All participants had measurable disease by RECIST v. 1.0 criteria. Both CT and PET scans were performed at Time 0, Time 1 and Time 2. Radiographic responses were quantified by the percentage of changes in the sum of all greatest tumor diameters between post- and pre-treatment scans. Institutional radiologists

### Table 3. Select studies of indoleamine 2,3 dioxygenase IDO in human cancers

| Neoplasm type | Stage | Tissue source | Sample size (n) for survival | Prognostic for survival | Reference |
|---------------|-------|---------------|------------------------------|-------------------------|-----------|
| Lung          | All   | Serum kyn/trp  | 123                          | Null                    | 24        |
| Breast        | I-III | Serum kyn/trp  | 33                           | n/a                     | 38        |
| Ovarian, serous | III-IV | Tumor IHC     | 24                           | Unfavorable             | 40        |
| Ovarian, epithelial | IC-IV | Tumor IHC     | 60                           | Unfavorable             | 51        |
| Renal cell    | IV    | Tumor mRNA    | 107                          | Favorable               | 52        |
| Hepatocellular| All   | Tumor IHC     | 138                          | Unfavorable             | 53        |
| Ovarian       | All   | Serum kyn/trp  | 28                           | n/a                     | 29        |
| Endometrial   | All   | Serum kyn/trp  | 41                           | n/a                     | 40        |
| Ovarian       | III-IV| Tumor IHC     | 122                          | Unfavorable             | 54        |
| Lung          | All   | Tumor IHC     | 28                           | n/a                     | 14        |
| Breast        | All   | Tumor mRNA    | 1059                         | Null                    | 55        |
| Oral squamous | All   | Tumor IHC     | 88                           | Unfavorable             | 56        |
| Breast        | All   | Tumor mRNA    | 30                           | Null                    | 57        |
| Colorectal    | All   | Tumor IHC     | 143                          | Unfavorable             | 58        |
| Colorectal    | All   | Tumor IHC     | 265                          | Unfavorable             | 59        |
| Endometrial   | All   | Tumor IHC     | 80                           | Unfavorable             | 60        |
| Pancreatic    | All   | Tumor IHC     | 17                           | n/a                     | 61        |
| Colorectal    | II-IV | Tumor IHC     | 69                           | n/a                     | 62        |
| Osteosarcoma  | All   | Tumor IHC     | 47                           | Unfavorable             | 63        |
| Esophageal, squamous | I-III | Tumor IHC | 45                           | n/a                     | 34        |
| Acute myelogenous leukemia | All | Tumor mRNA | 262                          | Unfavorable             | 37        |
| Melanoma, uveal | –     | Tumor IHC     | 7                            | n/a                     | 64        |
| Pancreatic IPMNs* | –     | Tumor IHC     | 39                           | n/a                     | 65        |
| Endometrial   | All   | Tumor IHC     | 355                          | Unfavorable             | 66        |
| Vulvar        | All   | Tumor IHC     | 286                          | Null                    | 67        |
| Melanoma      | III   | Tumor IHC     | 25                           | Unfavorable             | 68        |
| Melanoma      | I-III | Tumor IHC     | 26                           | n/a                     | 69        |
| Cervical      | n/a   | Tumor IHC     | 17                           | n/a                     | 70        |
| Hepatocellular| All   | Tumor mRNA    | 21                           | Favorable               | 71        |
| Colorectal    | All   | Tumor IHC     | 71                           | Unfavorable             | 72        |
| Lymphoma      | All   | Tumor IHC     | 119                          | Unfavorable             | 73        |
| Melanoma      | All   | Serum kyn/trp  | 87                           | Unfavorable             | 32        |
| Endometrial   | All   | Tumor IHC     | 65                           | Unfavorable             | 74        |
| Esophageal, squamous | All | Tumor mRNA | 30                           | Unfavorable             | 35        |
| Cervical      | IB-IIIB | Tumor IHC | 112                          | Unfavorable             | 75        |
| Thyroid       | All   | Tumor mRNA    | 20                           | Null                    | 36        |
| Melanoma      | All   | Tumor IHC     | 116                          | Unfavorable             | 76        |
| Lung, Non-small cell | n/a | Serum kyn/trp | 36                           | n/a                     | 25        |

Favorable, improved survival with higher IDO; unfavorable, worse survival with higher IDO; null, no difference observed; n/a, not tested; IHC, immunohistochemistry. *Intraductal papillary mucinous neoplasm.
evaluated all scans. OS was defined as the interval between the date of treatment and the date of death. PFS was defined as the interval between the date of treatment and the date of progression or death from any cause. Participants without an event were censored as of the date of last follow-up, which occurred between August and September 2009.

All procedures were approved by the Institution Review Board (IRB) from the University of South Florida (FWA00001669) and were in accordance with the Helsinki Declaration of 1975. Participants prospectively provided informed consent for the use of their tissue in research.

Measurement of plasma markers. Heparinized blood samples were drawn and centrifuged at 800 g for 10 min to extract plasma and then stored at −80°C. HPLC/MS/MS was performed with gradient elution on a C18 column (Thermo Betabasic, 150 mm × 2.1 mm, 5 μm particles) with matching guard column at a flow rate of 500 μL/min using heated electrospray ionization in the positive ion mode. Gradient solvents were 0.1% formic acid in water and acetonitrile with 0.1% formic acid (HPLC grade, Fisher-Scientific). The mass spectrometer (TSQ Quantum Ultra, Thermo) was operated in selected reaction monitoring mode (SRM). Calibration standards for Trp and Kyn (Fisher-Scientific) were prepared in albumin (Sigma) in the ranges of 10–2,000 ng/mL for Kyn and 100–20,000 ng/mL for Trp. Quality control samples were prepared in albumin at 10, 100, 1,000 ng/mL for Kyn and 100, 1,000, 10,000 ng/mL for Trp. 150 μL of internal standard solution containing Trp-d3 at 4,000 ng/mL and Kyn-d6 at 400 ng/mL (Cambridge Isotopes) were added and mixed to 150 μL of calibration standard, quality control, and clinical specimens. For protein precipitation, 30 μL of 2.4 M perchloric acid (Fisher-Scientific) were added, samples were vortexed and cooled for 5 min, then centrifuged at 20,400 g for 20 min. The supernatant was transferred to a filter tube (0.44 μm) and re-centrifuged. The filtered sample was transferred to a glass vial with 400 μL insert and 10 μL was injected onto the column. Each sample was performed in triplicate, and individual mean concentrations were recorded. The intraassay and day-to-day analytic coefficients of variation were less than 5% for each analyte (Table S1).

Statistics. The plasma concentrations of Kyn and Trp, as well as Kyn/Trp ratios approximated a parametric distribution. Therefore, data were presented as means ± SD. Due to the small sample size, the associations between serum biomarker levels and clinicopathologic variables were evaluated with Wilcoxon rank-sum and Kruskal-Wallis tests. Wilcoxon signed rank was used to compare between time points. Correlation was estimated using Spearman’s rho. Survival curves were calculated according to the Kaplan-Meier method. To address the experimental hypothesis, the statistical population was equally divided into “hig” and “low” patients using the median Kyn/Trp value as pre-specified cut-point. The effects of biomarkers on PFS and OS were evaluated using log-rank (Mantel-Cox) test and Cox proportional-hazards regression models. All tests performed were two-tailed. Statistical analysis was performed using the SAS software (version 8.0). Figures and survival plots were generated using GraphPad Prism® (version 5.04).

Disclosure of Potential Conflicts of Interest
The authors have no conflicts of interest to disclose.

Acknowledgments
This work was funded by NCI R01-CA102726 and P50-CA119997, and supported in part by the NIH/NCATS Clinical and Translational Science Award to the University of Florida UL1 TR000064. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Supplemental Material
Supplemental materials may be found here: http://www.landesbioscience.com/journals/oncoimmunology/article/23428/
12. Wobser M, Voigt H, Houwen R, Eggert AO, Firewaid M, Kaemmerer U, et al. Dendritic cell based anti-tumor vaccination: impact of functional indole-amine 2,3-dioxygenase expression. Cancer Immunol Immunother 2007; 56:1017-24; PMID:17195079; http://dx.doi.org/10.1007/s00262-006-0256-1.

13. Muller AJ, DufHawady JB, Donover PS, Sutanto-Ward E, Prentger GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11:312-9; PMID:15715557; http://dx.doi.org/10.1038/nm.1196.

14. Karanika V, Zamanakou M, Kerendi T, Dahabreh J, Herva A, Nakou M, et al. Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 2007; 6:1258-62; PMID:17700060.

15. Jenal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-304; PMID:20610545; http://dx.doi.org/10.3322/caac.20073.

16. SEER http://www.seer.cancer.gov 2000 - 2007.

17. Wobser M, Voigt H, Houben R, Eggert AO, Freiwald Kema IP. Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Sci 2009; 877:603-9; PMID:19195654; http://dx.doi.org/10.1016/j.jchromb.2009.01.015.

18. Vincent J, Mignon G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent anti-tumor immunity. Cancer Res 2010; 70:3052-61; PMID:20388795; http://dx.doi.org/10.1158/0008-5472.CAN-09-5609.

19. Meniawy TM, Nowak AK, Lake RA. Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity. Tumor Ablation 2013; 5:1-28; http://dx.doi.org/10.2147/CAOV.S24679.

20. Meniawy TM, Nowak AK, Lake RA. Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity. Tumor Ablation 2013; 5:1-28; http://dx.doi.org/10.2147/CAOV.S24679.
54. Takao M, Okamoto A, Nikaido T, Urashima M, Takakura S, Saito M, et al. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 2007; 17:1533-9; PMID:17487387.

55. Jacquierme J, Berrucci E, Finetti P, Esterni B, Charafe-Jauffret E, Thibault ML, et al. High expression of indoleamine-2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 2012; 130:96-104; PMID:21328335; http://dx.doi.org/10.1002/ijc.25979.

56. Laimer K, Triester B, Kloss F, Schafer G, Obrist P, Perathoner A, et al. Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. Oral Oncol 2011; 47:352-7; PMID:21440489; http://dx.doi.org/10.1016/j.oraloncology.2011.03.007.

57. Sakurai K, Amano S, Enomoto K, Kashio M, Saito Y, Laimer K, Troester B, Kloss F, Schafer G, Obrist P, Perathoner A, et al. Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. Oral Oncol 2011; 47:352-7; PMID:21440489; http://dx.doi.org/10.1016/j.oraloncology.2011.03.007.

58. Brandacher G, Perathoner A, Ladurner R, Schneeberger E, Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Lambert J, Haspeslagh M, et al. Prognostic role of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006; 12:1144-51; PMID:16489067; http://dx.doi.org/10.1158/1078-0432.CCR-05-034.

59. Ferdinande L, Deaestecer Cevert C, Verset L, Marhieu A, Moles Lopez X, Negulescu AM, et al. Clinicopathological significance of indoleamine-2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 2012; 106:141-7; PMID:22108515; http://dx.doi.org/10.1038/bjc.2011.513.

60. Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Ninomiya S, Hara T, Tsurumi H, Hoshi M, Kanemura N, Goto N, et al. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 2011; 90:409-16; PMID:20938662; http://dx.doi.org/10.1007/s00277-010-1093-x.

61. Takakura S, Saito M, Ishiguro N, Nakamura S, Ishiguro N. Prognostic value of indoleamine-2,3-dioxygenase expression in metastatic malignant melanoma recruiting regulatory T cells to avoid immunodeficiency. Melanoma Res 2006; 16:417-24; PMID:16870068; http://dx.doi.org/10.1097/01.yrm.0000207000.92090.7.

62. Chen PW, Mellon JK, Mayhew E, Wang S, He YG, Hogan N, et al. Uveal melanoma expression of indoleamine-2,3-dioxygenase: establishment of an immune privileged environment by tryptophan depletion. Exp Eye Res 2007; 85:617-25; PMID:17870068; http://dx.doi.org/10.1016/j.exer.2007.07.014.

63. Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S, Ishiguro N. Prognostic value of indoleamine-2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 2009; 26:1005-12; PMID:19802733; http://dx.doi.org/10.1007/s10585-009-9290-7.

64. Ishii T, Goto S, Takara K, Tone S, Kawano K, Kitano S. Immunoreactivcative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19:319-26; PMID:14748880; http://dx.doi.org/10.1111/j.1440-1746.2003.02329.x.

65. Kobayashi N, Kubota K, Kato S, Watanabe S, Shimamura T, Kizikoshi H, et al. FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraepithelial papillomatous neoplasms of the pancreas. Pancreatology 2010; 10:631-40; PMID:21051918; http://dx.doi.org/10.1159/000308966.

66. de Jong RA, Toppen NL, Ten Hoor KA, Boer HM, Kema IP, Hollema H, et al. Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma. Gynecol Oncol 2012; 126:474-80; PMID:22668882; http://dx.doi.org/10.1016/j.ygyno.2012.05.034.

67. Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Yeo CJ, et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cancer Cell 2009; 8:1930-4; PMID:19448397; http://dx.doi.org/10.1016/j.ccr.2009.07.045.

68. Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003; 83:1457-66; PMID:14563947; http://dx.doi.org/10.1038/sj.lnl.3201701. LAB.000809158.6852.D1.

69. Nakamura T, Shima T, Saki A, Hidaka T, Nakashima A, Takikawa O, et al. Expression of indoleamine 2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007; 98:874-81; PMID:17433937; http://dx.doi.org/10.1111/j.1349-7006.2007.00470.x.